There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > ORGANIZATION
ORGANIZATION
- Generic Trade Group Sets Out 4 Pledges on Quality, Stable Supply
September 15, 2021
- FPMAJ Vows to Work towards Achieving New Pharma Industry Vision
September 15, 2021
- Established Drugs’ Group Boots Up with 6 Firms Plus One Organization
September 14, 2021
- PhRMA Hails Japan's New Pharma Industry Vision
September 14, 2021
- JMA Think Tank Urges Discussions to Prep for Aducanumab Approval
September 8, 2021
- Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
September 6, 2021
- EFPIA Japan Issues Viewpoint on Cost Effectiveness Assessment System
August 31, 2021
- EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
- COVID-19 Oxygen Stations Should Provide Corticosteroids and Anticoagulants Too: JMA Executive
August 24, 2021
- New Established Medicines’ Association to Discuss Info Transfer Rules for LLP Withdrawals
August 20, 2021
- New Established Drugs’ Group Places Top Priority on Stable Generic Supply; Research-Driven and Foreign Firms to Join
August 20, 2021
- Generic Use Rate at 79.4% in FY2020, Up 2.5 Points: JGA
August 3, 2021
- New Industry Czar Vows to Balance Interests of Innovative Pharma, Gx Businesses as Budget Debate Creates Divide
July 30, 2021
- JPMA Reprimands Meiji Pharma over Kobayashi Kako Issue
July 16, 2021
- Hiroyuki Kawabata Joins PhRMA as Sr. Assistant Japan Representative
July 16, 2021
- Downloads of FPMAJ’s E-Labeling App on Track to Target 50,000 as Legal Enforcement Approaches
July 14, 2021
- Japan Patient Advocates Want Drugs for Later-Stage Alzheimer’s
July 13, 2021
- New Trade Group for Established Drugs to Launch in Japan
July 13, 2021
- FIRM Calls for Separate Pricing System for Regenerative Medicine Products: Chair
July 13, 2021
- JMA Frets Pricey Dementia Meds, to Explore Ways to Keep Universal Coverage
July 9, 2021
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…